MARKET

ITRM

ITRM

Iterum Therapeutics Plc
NASDAQ
1.630
+0.040
+2.52%
Opening 09:54 03/28 EDT
OPEN
1.620
PREV CLOSE
1.590
HIGH
1.670
LOW
1.620
VOLUME
51.53K
TURNOVER
0
52 WEEK HIGH
2.500
52 WEEK LOW
0.6220
MARKET CAP
21.90M
P/E (TTM)
-0.6689
1D
5D
1M
3M
1Y
5Y
Update: Iterum Therapeutics Q4 Adjusted EPS $(0.81) Beats $(0.94) Estimate
Benzinga · 4h ago
Iterum Therapeutics Non-GAAP EPS of -$0.81
Iterum Therapeutics sold 2.9 million ordinary shares under an at-the-market offering for $7.1 million. The company posted a Q4 non-GAAP EPS of -$0.81. The firm has a cash runway into 2025.
Seeking Alpha · 6h ago
Iterum Therapeutics Q4 2023 GAAP EPS $(0.94), Inline, Cash Position $23.9M
Benzinga · 6h ago
Earnings Scheduled For March 28, 2024
Universal Stainless is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Walgreens Boots Alliance is likely to report earnings for its fourth quarter. Companies Reporting Before The Bell include Shimmick and Universal Stainless. Companies reporting after the bell include INmune Bio and Oxford Industries.
Benzinga · 8h ago
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Barchart · 11h ago
Iterum Therapeutics's Earnings: A Preview
Iterum Therapeutics is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Analysts estimate the company will report an earnings per share of $-0.93. Last quarter the company missed EPS by $0.29. Shares of the company are up 57.25% in the last 52 weeks.
Benzinga · 1d ago
Notable earnings before Thursday's open
Seeking Alpha · 1d ago
Weekly Report: what happened at ITRM last week (0318-0322)?
Weekly Report · 3d ago
More
About ITRM
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Webull offers Iterum Therapeutics PLC stock information, including NASDAQ: ITRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITRM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITRM stock methods without spending real money on the virtual paper trading platform.